Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
grade C 9.94 -4.97% -0.52
ITCI closed down 4.97 percent on Friday, September 13, 2019, on 80 percent of normal volume. It was able to find support at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ITCI trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Pocket Pivot Bullish Swing Setup -4.97%
Calm After Storm Range Contraction -4.97%
Upper Bollinger Band Walk Strength -4.97%
Overbought Stochastic Strength -4.97%

Older signals for ITCI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
Medicine Biopharmaceutical Disorders Alzheimer's Disease Neuroscience Parkinson's Disease Schizophrenia Drug Development Psychiatry Psychiatric Diagnosis Treatment Of Parkinson's Disease Aging Associated Diseases Dementia Cognitive Disorders Human Diseases Major Depressive Disorders Bipolar Disorders Cardiovascular And Other Diseases Cognitive Dysfunction Cognitive Impairment Learning Disabilities
Is ITCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 23.62
52 Week Low 7.41
Average Volume 1,380,733
200-Day Moving Average 12.0579
50-Day Moving Average 9.5878
20-Day Moving Average 9.2
10-Day Moving Average 9.658
Average True Range 0.7105
ADX 17.97
+DI 22.6295
-DI 25.458
Chandelier Exit (Long, 3 ATRs ) 8.8685
Chandelier Exit (Short, 3 ATRs ) 10.364500000000001
Upper Bollinger Band 10.5961
Lower Bollinger Band 7.8039
Percent B (%b) 0.77
BandWidth 30.35
MACD Line 0.2044
MACD Signal Line -0.0151
MACD Histogram 0.2195
Fundamentals Value
Market Cap 431.64 Million
Num Shares 43.4 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -4.21
Price-to-Sales 2144.19
Price-to-Book 1.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.96
Resistance 3 (R3) 10.95 10.59 10.79
Resistance 2 (R2) 10.59 10.33 10.60 10.73
Resistance 1 (R1) 10.27 10.17 10.09 10.28 10.68
Pivot Point 9.91 9.91 9.83 9.92 9.91
Support 1 (S1) 9.59 9.65 9.41 9.60 9.20
Support 2 (S2) 9.23 9.49 9.24 9.15
Support 3 (S3) 8.91 9.23 9.09
Support 4 (S4) 8.92